Equity News
Akers Biosciences (AKER) Stock Spiked 30% on Merger Deal with MyMD Pharmaceuticals
Following the merger deal, Akers has also signed a Securities Purchase Agreementwith certain accredited investors to raise $18 million. Shares of Akers Biosciences, Inc. (AKER) soared on Thursday following the announcement of a merger deal with MyMD Pharmaceuticals. AKER spiked 30% at day’s close to $2.22, as the biotech is set to merge with MyMD. As per the definitive merger agreement, the combined company will be renamed MyMDPharmaceuticals, Inc., upon closing of the transaction.MyMD will remain listed on the Nasdaq under the new ticker “MYMD”. The combined company will work on the development and commercialization of MyMD’s novel immunotherapy pipeline
